Neo-Imuntech, a T cell-based immunotherapy development company, announced on the 30th that it has passed the preliminary examination for listing on the KOSDAQ market.
Neo-Imuntech plans to quickly submit a stock report and push forward a public offering procedure for IPO. We are promoting the listing of special technology, and the listing organizers are Hana Financial Investment and Mirae Asset Daewoo.(9,440 +1.61%)All.
Founded in 2014, Neo-Imuntech is developing a next-generation immune anticancer drug centering on T cells. Genexin(124,300 +1.06%)It is an affiliate of The head office is located in Maryland in the eastern United States, and it has a Korean subsidiary in Pangyo and a corporate-affiliated research center at Pohang University.
The main candidate is the new immunotherapy drug’NT-I7′. It is an explanation of the next-generation immune anticancer drug that induces the amplification of T cells. The company owns the copyrights in North America, Central America, South America and Europe.
It has signed joint clinical development contracts with pharmaceutical companies that have ranked 1st to 3rd in sales in the immuno-cancer field, such as Merck BMS Roche.
Yang Se-hwan, CEO of Neoimmuntech, said, “We want to focus on global clinical trials that are currently being promoted after the IPO. We will leap forward as a leading company in the global anticancer drug market through listing.”
Neoimmuntech recently received approval from the US Food and Drug Administration (FDA) for a phase 2 clinical trial for the first-line treatment of non-small cell lung cancer in combination with NT-I7 and Roche Ticentric. Phase 1 clinical trials of the novel coronavirus infection (Corona 19) also started the first clinical patient administration last month.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution